Physician profile
Michael Dempewolf
NPI 1558654392
$9,014.52
in general payments reported to CMS, 2019-2025
19 companies · $996 in 2025
The $996 reported for 2025 was more than what a typical Sports Medicine (Orthopaedic Surgery) provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,723 · 2020: $1,748 · 2021: $2,506 · 2022: $240 · 2023: $335 · 2024: $466 · 2025: $996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,097 · Travel and Lodging: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,096.75 |
| Travel and Lodging | $700.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $2,738.09 | 2019-2025 | |
| Titan Surgical Group, LLC | $2,324.65 | 2020-2025 | |
| Anika Therapeutics, INC. | $1,200.00 | 2021 | |
| Smith+Nephew, INC. | $1,109.74 | 2019 | |
| Electronic Waveform Lab, INC. | $617.89 | 2019-2025 | |
| Stryker Corporation | $168.60 | 2020-2024 | Variax, Iconix, Knotilus Anchor, 3.5mm |
| Linvatec Corporation | $161.03 | 2023-2025 | Biobrace 23mm, Hall Power |
| Zimmer Biomet Holdings, INC. | $142.77 | 2023 | |
| Terumo Medical Corporation | $141.32 | 2024 | Glidewire, Azur Cx Detachable, Hydropearl |
| Innovation Technologies INC | $132.78 | 2022 | |
| Depuy Synthes Sales INC. | $58.98 | 2019-2025 | Orthovisc, Monovisc |
| Pacira Therapeutics, INC. | $40.65 | 2020-2021 | |
| Ossur Americas, INC. | $40.50 | 2024 | Miami J |
| Pfizer INC. | $35.51 | 2019-2020 | |
| Djo, LLC | $35.20 | 2025 | Cmf |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $18.20 | 2021 | |
| Averitas Pharma INC. | $18.03 | 2025 | Qutenza |
| Ibsa Pharma INC. | $16.57 | 2024 | Licart, Tirosint |
| Integra Lifesciences Corporation | $14.01 | 2024 | Tenoglide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dempewolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.